Precision BioSciences Q2 2026: Wider Loss on Non-Cash Warrant Charge, But Cash Runway Through 2028 and Promising HBV/DMD Data
DTIL sits 94% above its 52-week low of $3.53.
Summary
A wider Q2 net loss was driven by a non-cash warrant liability charge, but Precision BioSciences ended the quarter with $112.4M in cash, enough to fund operations through 2028. Positive clinical updates for the HBV and DMD gene editing programs were provided, with key data milestones expected by year-end 2026.
Key Events · Earnings and Guidance · DTIL
-
Q2 Net Loss Wider on Non-Cash Charge
Net loss of $32.7M ($1.26/share) vs $23.5M ($2.13/share) in Q2 2025, driven by a $13.9M non-cash loss from warrant liability fair value adjustment due to stock price appreciation. This does not impact cash or operations.
-
Cash Runway Through 2028
Cash, cash equivalents, and restricted cash totaled $112.4M as of June 30, 2026. Management expects this, along with fiscal discipline and the ATM facility, to fund operations through 2028, covering key data milestones for PBGENE-HBV and PBGENE-DMD.
-
PBGENE-HBV Clinical Proof-of-Concept
First clinical biopsy evidence of direct cccDNA elimination: a 1-log reduction with <1% remaining after two doses. Sustained pgRNA loss in 100% of evaluable patients. No dose-limiting toxicities. Additional updates expected by year-end 2026.
-
PBGENE-DMD Trial Advancing
Phase 1/2 FUNCTION-DMD trial now actively recruiting at two sites (Arkansas Children's, Washington University). Initial safety data expected by year-end 2026. Program eligible for Priority Review Voucher.
Analysis · DTIL · Life Sciences
A wider-than-expected Q2 net loss of $32.7 million, or $1.26 per share, stemmed from a $13.9 million non-cash charge tied to the revaluation of warrant liabilities as the stock price rose—an accounting adjustment that leaves cash and operations untouched. More importantly, the company closed the quarter with $112.4 million in cash, a balance management believes will fund operations through 2028 and cover key data milestones for its wholly owned gene editing programs, PBGENE-HBV and PBGENE-DMD. On the clinical front, the first-ever biopsy evidence showed that PBGENE-HBV can directly eliminate cccDNA in chronic hepatitis B patients, with sustained loss of pgRNA in all evaluable patients. Meanwhile, the DMD program is actively recruiting at two sites, and initial safety data are expected by year-end 2026. The filing also notes recent leadership changes and addition to the Russell 2000 Index. The non-cash loss is a mark-to-market adjustment, not a cash outflow or new dilution, and the strong cash position and clinical progress are the key takeaways.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 35% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DTIL was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.7M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.